Cargando…
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy
Polo-like kinase 1, a pivotal regulator of mitosis and cytokinesis, is highly expressed in a broad spectrum of tumors and its expression correlates often with poor prognosis, suggesting its potential as a therapeutic target. p53, the guardian of the genome, is the most important tumor suppressor. In...
Autores principales: | Louwen, Frank, Yuan, Juping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759674/ https://www.ncbi.nlm.nih.gov/pubmed/23948487 |
Ejemplares similares
-
Loss of p21(Cip1/CDKN1A) renders cancer cells susceptible to Polo-like kinase 1 inhibition
por: Kreis, Nina-Naomi, et al.
Publicado: (2014) -
The activity regulation of the mitotic centromere-associated kinesin by Polo-like kinase 1
por: Ritter, Andreas, et al.
Publicado: (2014) -
Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells
por: Ritter, Andreas, et al.
Publicado: (2016) -
Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis
por: Sanhaji, Mourad, et al.
Publicado: (2014) -
Extracellular vesicles in bone: “dogrobbers” in the “eternal battle field”
por: Tao, Shi-Cong, et al.
Publicado: (2019)